US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment
Sydney, Australia 28 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer is open for recruitment. COBRA (COpper-64 SAR-BisPSMA in Biochemically Recurrent prostAte cancer) is a Phase I/II Positron Emission…